WEB ANNEX J. TABLE OF DRUG INTERACTIONS WITH ANTIRETROVIRAL DRUGS

Similar documents
GUIDANCE FOR SAMPLING ART CLINICS IN COUNTRIES COMBINING SURVEILLANCE OF PRE-TREATMENT HIV DRUG RESISTANCE AND ACQUIRED HIV DRUG RESISTANCE AT 12 AND

Latent tuberculosis infection

WEB ANNEX I. REPORT ON COST-EFFECTIVENESS OF IMPLEMENTING AN INDETERMINATE RANGE FOR EARLY INFANT DIAGNOSIS OF HIV

BEST PRACTICES IN MICROPLANNING FOR CHILDREN OUT OF THE HOUSEHOLD: AN EXAMPLE FROM NORTHERN NIGERIA

Raising tobacco taxes in Bangladesh in FY : An opportunity for development

WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC,

BEST PRACTICES FOR PLANNING A VACCINATION CAMPAIGN FOR AN ENTIRE POPULATION

Summary report on the WHO-EM/WRH/104/E

1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017

Latent tuberculosis infection

SUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect: Darunavir Alvogen 400 mg: Each tablet contains mg sunset yellow FCF (E110).

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

4. Timing of post-abortion contraception

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

The ART of Managing Drug-Drug Interactions in Patients with HIV

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs

ANTI-HIV DRUG INTERACTIONS. a guide to the interactions found between anti-hiv drugs and common hiv-related therapies

New York State HCV Provider Webinar Series. Drug-Drug Interactions Including PPIs

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

UPDATE ON ANTIRETROVIRAL REGIMENS FOR TREATING AND PREVENTING HIV INFECTION AND UPDATE ON EARLY INFANT DIAGNOSIS OF HIV

ANTIRETROVIRAL CONTRAINDICATIONS AND DRUG INTERACTIONS (Part 1 of 8) 10)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

HIV TREATMENT INTERIM

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting

SUMMARY OF PRODUCT CHARACTERISTICS

Pharmacological considerations on the use of ARVs in pregnancy

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PROGRAM General Information

ART and Prevention: What do we know?

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Web Annex 3.1. Adult hepatitis C virus treatment systematic review

SUMMARY OF PRODUCT CHARACTERISTICS

Comprehensive Guideline Summary

WHO IMPLEMENTATION TOOL FOR PRE-EXPOSURE PROPHYLAXIS (PrEP) OF HIV INFECTION

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Each film-coated tablet contains 12.5 mg of ombitasvir, 75 mg of paritaprevir and 50 mg of ritonavir.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

WEB ANNEX B. SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS ASSESSING FIRST-LINE ART TREATMENTS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Multidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017

PREZISTA. darunavir DATA SHEET

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

Supplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir

Transaction Prices for Antiretroviral Medicines from 2010 to Global Price Reporting Mechanism

Summary report on the WHO-EM/CSR/124/E

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

ANTIRETROVIRAL TREATMENTS (Part 1of

Appendix 5: Hepatic impairment

Package leaflet: Information for the user

HIV/AIDS Update 2007

preventing suicide Regional strategy on

HIV Treatment: New and Veteran Drugs Classes

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Evidence on Hormonal Contraception & ART Interactions. HC-HIV Meeting Lusaka, Zambia October 22, 2015 Jennifer Tang, MD, MSCR

Antiretroviral Dosing in Renal Impairment

HIV and contraception the latest recommendations

The Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland

Recommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

Domperidone: Drug Interactions & Cautions (Mayo Clinic)

Simplifying HIV Treatment Now and in the Future

SUMMARY OF PRODUCT CHARACTERISTICS

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

HIV Drugs and the HIV Lifecycle

What's new in the WHO ART guidelines How did markets react?

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Slide 1 Will DAA drug interactions matter in the future? David Back. David Back University of Liverpool UK. University of Liverpool June 2015

Genvoya FACTSHEET. Summary. Inside Genvoya. Common side effects. Studies

Genvoya approved in Canada What you need to know

WHO-PQ RECOMMENDED SUMMARY OF PRODUCT CHARACTERISTICS

Criteria for Oral PrEP

Toolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES

The Global Health Impact Index

PRODUCT MONOGRAPH. fosamprenavir calcium tablet, 700 mg fosamprenavir. fosamprenavir calcium oral suspension, 50 mg/ml fosamprenavir

Appendix 1: Interactions

Transaction Prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to July 2011

HIV for the Non-ID Pharmacist

Clarification Memo # 1 to:

Invitation to Manufacturers 16 August 2017

PRODUCT MONOGRAPH. Fosamprenavir tablets 700 mg (as fosamprenavir calcium) Fosamprenavir oral suspension 50 mg/ml (as fosamprenavir calcium)

PREZCOBIX Tablets Darunavir/cobicistat Consumer Medicine Information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

NEW ZEALAND DATA SHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline

Susan L. Koletar, MD

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

Antiretroviral Drugs

Transcription:

WEB ANNEX J. TABLE OF DRUG INTERACTIONS WITH ANTIRETROVIRAL DRUGS In: Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

WHO/CDS/HIV/18.33 World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Web Annex J. Drug interactions with antiretroviral drugs. In: Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2018 (WHO/CDS/HIV/18.33). Licence: CC BY-NC- SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. This publication forms part of the WHO guideline entitled Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. It is being made publicly available as supplied by those responsible for its development for transparency purposes and information, as required by WHO (see the WHO handbook for guideline development, 2nd edition (2014)).

Contents Abbreviations... 5 Table of drug interactions with antiretroviral drugs... 6 Key to table:... 6 References... 14

Abbreviations ABC TDF AZT 3TC ddi FTC d4t ATV LPV DRV RTV EFV ETR NVP RPV DTG RAL EVG/COB abacavir tenofovir disoproxil fumarate zidovudine lamivudine didanosine emtricitabine stavudine atazanavir lopinavir darunavir ritonavir efavirenz etravirine nevirapine rilpivirine dolutegravir raltegravir elvitegravir/cobicistat

Table of drug interactions with antiretroviral drugs Key to table: Unknown/no data Weak potential interaction Potential interaction that may require close monitoring, alteration of drug dose or timing Interaction likely, should not be co'administered No interaction expected No interaction expected, limited data *cross hatches indicate the interaction may/may not occur, and there is limited data

Anti/Tubercular Drugs ABC TDF AZT 3TC ddi FTC d4t ATV LPV DRV RTV EFV ETR NVP RPV DTG RAL EVG/COB Bedaquiline Cycloserine Ethambutol Ethionamide Isoniazid Kanamycin Pyrazanamide Rifabutin Rifampicin Rifapentine Trimethoprim/Sulfamet hoxazole Antihistamines Astemizole Cetirizine Chlorphenamine Diphenhydramine Fexofenadine Levocetirizine Loratadine Promethazine Terfenadine

Contraceptive&HRT Desogestrel (COC) Desogestrel (POP) Drospirenone (COC) Drospirenone (HRT) Dydrogesterone (HRT) Estradiol Ethinylestradiol Etonogestrel (imp) Etonogestrel (ring) Gestodene Levonorgesterel (COC) Levonorgesterel (Emergency) Levonorgesterel(HRT) Levonorgesterel (IUD) Levonorgesterel (POP) Levonorgesterel (implant) Medroxyprogesterone (IM Depot) oral Medroxyprogesterone Norelgestromin patch Norethisterone (COC) Norethisterone (HRT) Norethisterone (IM Depot) Norethisterone (POP) Norgestimate (COC) Norgestrel (COC) Norgestrel (HRT) Ulipristal

Sedative & anxiolytics Alprazolam Midazolam (Injection) Midazolam (oral) Triazolam Diazepam Gastrointestinal medications Omeprazole Cisapride Esomeprazole Lansoprazole Pantoprazole Rabeprazole Metoclopromide Antacids Senna Cardiovascular drugs (Anti-arrhythmics) Amiodarone Bepridil Disopyramide Dofetilide Flecainide Lidocaine Mexiletine Propafenone Quinidine Dabigatran Rivaroxaban Simvastatin Lovastatin Lercanidipine Pravastatin Amlodipine Bisoprolol Enalapril Hydralazine Hydrochlorothiazide Bendroflumethazide Methyldopa

Anti-psychotics Fluphenazine Haloperidol Pimozide Risperidone Antidepressants and mood stabilisers Lithium Amitryptiline Bupropion Citalopram Clomipramine Doxepine Escitalopram Fluoxetine Imipramine Mirtazepine Nortryptiline Paroxetine Sertraline Trazodone Venlafaxine Anti-migraine Ergotamine Dihydroergotamine Anticonvulsants Carbamazepine Phenobarbital Phenytoin Gabapentin Oxcarbazepine Valproic acid

Antiretrovirals (Integrase inhibitors) EVG/COB Dolutegravir Raltegravir Antiretrovirals (NRTIs) Abacavir Didanosine Emcitrabine Lamivudine Stavudine Tenofovir Zidovudine Antiretrovirals (Protease Inhibitors) Atazanavir Darunavir Lopinavir Ritonavir Saquinavir Hepatitis drugs Ribavirin Adefovir Peginterferon Alpha2a Telaprevir Bocreprevir Entecavir Ganciclovir Aciclovir Sofosbuvir Ledipasvir/Sofosbuvir Daclatasvir Simeprevir Tenofovir Telbivudine

Anti-parasitic Metronidazole Albendazole Spectinomycin Anti-malarials Amodiaquine Artemisinin Halofantrine Pyrimethamine Sulfadoxine Lumefantrine Mefloquine Anti-fungals Itraconazole Ketoconazole Voriconazole Fluconazole Amphotericin B Flucytosine Recreational drugs Marijuana (cannabis) Cocaine Alcohol Methamphetamines GHB Ecstasy Amyl nitrate (poppers) Ketamine LSD Heroin Mephedrone

Anti-diabetic drugs Insulin Gliclazide Glucagon Metformin Supplements Ascorbic Acid (Vitamin C) Cholecalciferol (Vitamin D3) Cyanocobalamin (Vitamin B12) Phytomenadione (Vitamin K) Pyridoxine (Vitamin B6) Folic Acid Retinol (Vitamin A) Riboflavin (Vitamin B2) Thiamine (Vitamin B1) Vitamin E Magnesium Iron Zinc Calcium Other drugs Hydroxyurea Sildenafil - pulmonary arterial hypertension Sildenafil - erectile dysfunction Allopurinol Alfuzosin Dexamethasone Piroxicam St Johns Wort Orlistat

References University of Liverpool. HIV drug interactions. Available from: https://www.hivdruginteractions.org/checker [accessed August 2018]